BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19760767)

  • 1. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry.
    Mejstríková E; Fronková E; Kalina T; Omelka M; Batinić D; Dubravcić K; Pospísilová K; Vásková M; Luria D; Cheng SH; Ng M; Leung Y; Kappelmayer J; Kiss F; Izraeli S; Stark B; Schrappe M; Trka J; Starý J; Hrusák O
    Pediatr Blood Cancer; 2010 Jan; 54(1):62-70. PubMed ID: 19760767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.
    Robillard N; Cavé H; Méchinaud F; Guidal C; Garnache-Ottou F; Rohrlich PS; Avet-Loiseau H; Garand R
    Haematologica; 2005 Nov; 90(11):1516-23. PubMed ID: 16266899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
    Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
    Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Jiang LM; Zhao JC; Chen J; Pan C; Dong L; Chen J; Xue HL; Tang JY; Wang YP
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):246-50. PubMed ID: 19374803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
    Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
    Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
    Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
    Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
    Szczepański T; Flohr T; van der Velden VH; Bartram CR; van Dongen JJ
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):37-57. PubMed ID: 11987915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.
    Solly F; Angelot F; Garand R; Ferrand C; Seillès E; Schillinger F; Decobecq A; Billot M; Larosa F; Plouvier E; Deconinck E; Legrand F; Saas P; Rohrlich PS; Garnache-Ottou F
    Cytometry A; 2012 Jan; 81(1):17-24. PubMed ID: 22052678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia.
    Thörn I; Botling J; Hermansson M; Lönnerholm G; Sundström C; Rosenquist R; Barbany G
    Leuk Res; 2009 Aug; 33(8):1047-54. PubMed ID: 19157547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of a new strategy for minimal residual disease monitoring in children with B-precursor acute lymphoblastic leukemia].
    Bonjean B; Grollet L; Visentin E; Sigaux F; Cayuela JM
    Ann Biol Clin (Paris); 2004; 62(4):465-70. PubMed ID: 15297244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease.
    van der Velden VH; de Bie M; van Wering ER; van Dongen JJ
    Haematologica; 2006 May; 91(5):679-82. PubMed ID: 16627258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pattern of clonal immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Chinese adult acute lymphoblastic leukemia patients.
    Yao L; Chen Z; Cen J; Liang J; Feng Y; He J; Qi X; Shen H
    Leuk Res; 2008 Nov; 32(11):1735-40. PubMed ID: 18456325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular detection of minimal residual disease is associated with early relapse in adult acute lymphoblastic leukemia.
    Specchia G; Liso A; Pannunzio A; Albano F; Mestice A; Pastore D; Liso V
    Haematologica; 2004 Oct; 89(10):1271-3. PubMed ID: 15477219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL.
    Fronkova E; Muzikova K; Mejstrikova E; Kovac M; Formankova R; Sedlacek P; Hrusak O; Stary J; Trka J
    Bone Marrow Transplant; 2008 Aug; 42(3):187-96. PubMed ID: 18490915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
    Ruiz-Argüelles GJ; Fernández-Lara D; Estrada-Gómez R; Manzano C; Ruiz-Delgado GJ; Pérez-Romano B; Ruiz-Argüelles A
    Lab Hematol; 2007; 13(1):22-6. PubMed ID: 17353179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.